Evidence map›Paper›PMID 35048158›Full record

ArticleCellular and molecular life sciences : CMLS2022

WNT/beta-catenin signalling interrupts a senescence-induction cascade in human mesenchymal stem cells that restricts their expansion.

Johannes Lehmann, Roberto Narcisi, Natasja Franceschini, Danai Chatzivasileiou, Cindy G Boer, Wendy J L M Koevoet, Diana Putavet, Dubravka Drabek, Rien van Haperen, Peter L J de Keizer and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Cellular senescence in skeletal disease: mechanisms and treatment.Cellular & molecular biology letters · 2023
    Review
  18. Cellular senescence in glioma.Journal of neuro-oncology · 2023
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Johannes LehmannDepartment of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0002-2833-4411
Roberto NarcisiDepartment of Orthopaedics and Sports Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0003-0521-8618
Natasja FranceschiniDepartment of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Danai ChatzivasileiouDepartment of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Cindy G BoerDepartment of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Wendy J L M KoevoetDepartment of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Diana PutavetCenter for Molecular Medicine, Section Molecular Cancer Research, Division LAB, University Medical Center Utrecht, Utrecht, The Netherlands.
Dubravka DrabekDepartment of Cell Biology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Rien van HaperenDepartment of Cell Biology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Peter L J de KeizerCenter for Molecular Medicine, Section Molecular Cancer Research, Division LAB, University Medical Center Utrecht, Utrecht, The Netherlands.
Gerjo J V M van Osch *Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0003-1852-6409
Derk Ten Berge *Department of Cell Biology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands. d.tenberge@erasmusmc.nl.ORCID http://orcid.org/0000-0002-5863-0860
Erasmus MC · NL

Funding

ffg CartiScaffKWF Kankerbestrijding UMCU7141ZonMw 116006104
6 · The paper itself

Abstract

Senescence, the irreversible cell cycle arrest of damaged cells, is accompanied by a deleterious pro-inflammatory senescence-associated secretory phenotype (SASP). Senescence and the SASP are major factors in aging, cancer, and degenerative diseases, and interfere with the expansion of adult cells in vitro, yet little is known about how to counteract their induction and deleterious effects. Paracrine signals are increasingly recognized as important senescence triggers and understanding their regulation and mode of action may provide novel opportunities to reduce senescence-induced inflammation and improve cell-based therapies. Here, we show that the signalling protein WNT3A counteracts the induction of paracrine senescence in cultured human adult mesenchymal stem cells (MSCs). We find that entry into senescence in a small subpopulation of MSCs triggers a secretome that causes a feed-forward signalling cascade that with increasing speed induces healthy cells into senescence. WNT signals interrupt this cascade by repressing cytokines that mediate this induction of senescence. Inhibition of those mediators by interference with NF-κB or interleukin 6 signalling reduced paracrine senescence in absence of WNT3A and promoted the expansion of MSCs. Our work reveals how WNT signals can antagonize senescence and has relevance not only for expansion of adult cells but can also provide new insights into senescence-associated inflammatory and degenerative diseases.

Indexed as

Senescence-Associated Secretory PhenotypeWnt Signaling PathwayCell ProliferationCells, CulturedHumansMesenchymal Stem CellsMiddle AgedWnt3A ProteinWnt3A ProteinWNT3A protein, humanCell cycleMultipotent stromal cellsParacrine senescenceSecondary senescence

Identifiers

PMID35048158
PMCPMC8770385
OpenAlexW4206728900

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.